# Intellia Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Intellia Therapeutics, Inc.). ## Overview Intellia Therapeutics is a clinical-stage biopharmaceutical company built around CRISPR-based gene editing and related delivery technologies. It is developing potentially curative therapies for severe genetic diseases, with its lead programs lonvoguran ziclumeran (NTLA-2002) for hereditary angioedema and nexiguran ziclumeran (NTLA-2001) for ATTR amyloidosis in Phase 3 development. ## Products & services • CRISPR/Cas9 gene editing therapeutics • Lonvoguran ziclumeran (NTLA-2002) for hereditary angioedema • Nexiguran ziclumeran (NTLA-2001) for ATTR amyloidosis • Oligonucleotide and lipid nanoparticle delivery technologies • Collaboration-based R&D and technology access licenses - **In vivo gene editing therapeutics** (0%) — Systemically administered CRISPR-based drug candidates designed to durably edit disease-causing genes in the body. - **Lead clinical programs** (0%) — NTLA-2002 and NTLA-2001, the company's most advanced programs targeting HAE and ATTR amyloidosis. - **Delivery platform technologies** (0%) — Oligonucleotide and lipid nanoparticle tools used to enable targeted in vivo gene editing. - **Collaboration revenue** (100%) — Upfront fees, research funding, cost reimbursements, and milestones from strategic partners. - CRISPR/Cas9 genome editing therapeutics - Lonvoguran ziclumeran (NTLA-2002) for hereditary angioedema - Nexiguran ziclumeran (NTLA-2001) for ATTR amyloidosis - Oligonucleotide and lipid nanoparticle delivery technologies - Collaboration-based research, licenses, and milestone programs ## Customers Intellia does not yet sell approved medicines directly to patients; its current customers are collaboration partners that pay for access to its technology, research support, and development rights. If its lead programs are approved, the end customers would be specialty physicians and patients with severe genetic diseases such as hereditary angioedema and ATTR amyloidosis. - **Strategic collaboration partners** (primary) — Regeneron, AvenCell, SparingVision, Kyverna, ONK, and ReCode pay for technology access, research support, and milestone-linked development rights. - **Patients with hereditary angioedema** (primary) — Future end users of lonvoguran ziclumeran, a one-time IV gene-editing therapy intended to reduce disease burden and attack frequency. - **Patients with ATTR amyloidosis** (primary) — Future end users of nexiguran ziclumeran, designed to address the root cause of transthyretin amyloid disease. - **Specialty physicians and treatment centers** (secondary) — Prescribers and infusion sites that would adopt and administer approved therapies in outpatient settings. - Pharma and biotech collaborators funding CRISPR programs - Patients with severe genetic diseases, if products are approved - Specialty physicians treating HAE and ATTR amyloidosis - Potential distributors or commercial partners for launch - Research partners using Intellia's platform and know-how ## Geography Intellia is headquartered in the United States and its business is centered on U.S.-based research, development, and clinical operations. The company also relies on global collaboration and clinical/regulatory pathways, but the filings provided do not disclose a country-by-country revenue split. - Headquartered and primarily operated in the United States - Clinical development and corporate functions are U.S.-centered - Collaborations create exposure to global partner and trial activity - No country-level revenue disclosure was provided in the excerpts ## Strategy Intellia is focused on advancing its in vivo CRISPR platform through late-stage clinical development and preparing for a planned first commercial launch of lonvo-z in the first half of 2027. Near term, it is prioritizing delivery technology, manufacturing readiness, regulatory execution, and collaboration funding to extend runway and reduce dependence on equity financing. - **Phase 3 execution for lead programs** (short-term) — Clinical success is the main value driver and prerequisite for approval and commercialization. - **Commercial launch preparation** (medium-term) — The company expects a potential first launch in 2027 and must build launch capabilities or partner for them. - **Platform and delivery optimization** (medium-term) — Better delivery and editing performance improve probability of success across current and future programs. - **Capital efficiency through collaborations** (short-term) — Collaboration revenue and reimbursements help fund operations before product sales begin. - Advance NTLA-2002 and NTLA-2001 through Phase 3 - Prepare for first commercial launch of lonvo-z in 2027 - Improve delivery technologies and scalable manufacturing - Use collaborations to fund R&D and broaden platform reach - Protect and expand IP around CRISPR and delivery systems ## Risks Intellia faces the core risks of a clinical-stage gene-editing company: unproven technology, lengthy trials, regulatory uncertainty, and dependence on third parties for manufacturing and commercialization. It also has no current sales infrastructure, so even approval would require either building commercial capabilities or securing partners, while ongoing losses and capital needs remain material. - **Clinical development failure** [critical] — Lead programs are still in Phase 3, and adverse efficacy or safety data could eliminate commercialization prospects. - **Unproven CRISPR platform** [high] — The company itself notes that CRISPR/Cas9 genome editing has only recently been clinically validated for human use. - **Manufacturing and supply chain dependence** [high] — Clinical and future commercial supply rely on third parties for inputs, quality, and capacity. - **Commercialization execution risk** [high] — The company has no sales, marketing, or distribution infrastructure and may need to build one or partner. - **Financing and dilution risk** [high] — The business remains loss-making and may need additional capital before product revenue begins. - CRISPR therapies are still clinically unproven at scale - Phase 3 trials may fail, delay, or require more capital - Manufacturing depends on third-party suppliers and CMOs - No sales or distribution infrastructure exists today - Future commercialization may require costly partner deals - Continued losses and dilution risk remain significant ## Accounting The most important accounting judgments are revenue recognition for collaboration arrangements, accrued R&D expenses, and stock-based compensation. Reported revenue can shift with milestone timing, cost reimbursements, and contract terminations, while fair value changes in investments and contingent consideration can add volatility below operating income. - **Collaboration revenue recognition** — Can create quarter-to-quarter volatility in reported revenue - **Accrued research and development expenses** — Affects operating expense timing and loss recognition - **Stock-based compensation** — Raises operating expenses without immediate cash outflow - **Fair value measurements** — Can affect net loss and other income - **Lease accounting** — Affects assets, liabilities, and non-cash disclosures - Collaboration revenue depends on milestones and cost reimbursements - R&D accruals affect timing of clinical and manufacturing expenses - Stock-based compensation is a major non-cash operating expense - Fair value changes in investments can move other income or loss - Lease accounting and right-of-use assets affect balance sheet totals --- *Last updated: 2026-04-28T20:17:46.370536+00:00*